A novel EGFR isoform confers increased invasiveness to cancer cells

Cancer Research

Volumn 73, Issue 23, 2013, Pages 7056-7067

  Zhou, Min ^a   Wang, Hai ^a   Zhou, Keke ^b   Luo, Xiaoying ^a   Pan, Xiaorong ^a   Shi, Bizhi ^a   Jiang, Hua ^a   Zhang, Jiqin ^a   Li, Kesang ^a   Wang, Hua Mao ^a   Gao, Huiping ^a   Lu, Shun ^c   Yao, Ming ^a   Mao, Ying ^b   Wang, Hong Yang ^a,d   Yang, Shengli ^a   Gu, Jianren ^a   Li, Chuanyuan ^e   Li, Zonghai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; ISOPROTEIN; MICRORNA; MICRORNA 542 5P; SERINE; STAT3 PROTEIN; THREONINE; TYROSINE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PROGNOSIS; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; EGFR GENE; FEEDBACK SYSTEM; FEMALE; GENE; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GLIOMA; HB EGF GENE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR INVASION; UPREGULATION;

EID: 84890284198     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0194     Document Type: Article

References (40)

1. Fondacci C, Alsat E, Gabriel R, Blot P, Nessmann C, Evain-Brion D. Alterations of human placental epidermal growth factor receptor in intrauterine growth retardation. J Clin Invest 1994;93:1149-55.
2. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009;21:177-84.
3. Khazaie K, Schirrmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 1993;12:255-74.
4. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 2006;12:7261-70.
5. Kamath S, Buolamwini JK. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev 2006;26:569-94.
6. Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broet P, et al. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer 2004;91:470-5.
7. Kallio JP, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Luukkaala T, Tammela TL, et al. Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma. Br J Cancer 2003;89:1266-9.
8. Bredel M, Pollack IF, Hamilton RL, James CD. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999;5:1786-92.
9. Zlobec I, Vuong T, Hayashi S, Haegert D, Tornillo L, Terracciano L, et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer 2007;96:793-800.
10. Karpel-Massler G, Schmidt U, Unterberg A, Halatsch ME. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol Cancer Res 2009;7:1000-12.
11. Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 2009;6:500-12.
12. Gusterson BA, Hunter KD. Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncol 2009;10:522-7.
13. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008;456:470-6.
14. Yi Q, Tang L. Alternative spliced variants as biomarkers of colorectal cancer. Curr Drug Metab 2011;12:966-74.
15. Rajan P, Elliott DJ, Robson CN, Leung HY. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 2009;6:454-60.
16. Planque C, Choi YH, Guyetant S, Heuze-Vourc'h N, Briollais L, Courty Y. Alternative splicing variant of kallikrein-related peptidase 8 as an independent predictor of unfavorable prognosis in lung cancer. Clin Chem 2010;56:987-97.
17. Reiter JL, Threadgill DW, Eley GD, Strunk KE, Danielsen AJ, Sinclair CS, et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics 2001;71:1-20.
18. Reiter JL, Maihle NJ. A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucleic Acids Res 1996;24:4050-6.
19. Reiter JL, Maihle NJ. Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta. Ann N Y Acad Sci 2003;995:39-47.
20. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96.
21. Wang H, Zhou M, Shi B, Zhang Q, Jiang H, Sun Y, et al. Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 2011;13:461-71.
22. Torp SH, Gulati S, Johannessen E, Dalen A. Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study. J Exp Clin Cancer Res 2007;26:353-9.
23. Zhao LL, Xu KL, Wang SW, Hu BL, Chen LR. Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas. Histopathology 2012;61:726-736.
24. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995;55:5536-9.
25. Bray I, Tivnan A, Bryan K, Foley NH, Watters KM, Tracey L, et al. microRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett 2011;303:56-64.
26. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A 2002;99:16899-903.
27. Devarajan E, Huang S. STAT3 as a central regulator of tumor metastases. Curr Mol Med 2009;9:626-33.
28. Yagi H, Yotsumoto F, Miyamoto S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther 2008;7:3441-51.
29. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005;7:575-89.
30. Singh NK, Wang D, Kundumani-Sridharan V, Van Quyen D, Niu J, Rao GN. 15-Lipoxygenase-1-enhanced Src-Janus kinase 2-signal transducer and activator of transcription 3 stimulation and monocyte chemoattractant protein-1 expression require redox-sensitive activation of epidermal growth factor receptor in vascular wall remodeling. J Biol Chem 2011;286:22478-88.
31. Haura EB, Turkson J, Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract 2005;2:315-24.
32. Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1997;1333:F179-99.
33. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999;274:8335-43.
34. Shan Y, Eastwood MP, Zhang X, Kim ET, Arkhipov A, Dror RO, et al. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 2012;149:860-70.
35. Xia L, Wang L, Chung AS, Ivanov SS, Ling MY, Dragoi AM, et al. Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem 2002;277:30716-23.
36. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009;284:5731-41.
37. Katakowski M, Zheng X, Jiang F, Rogers T, Szalad A, Chopp M. MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest 2010;28:1024-30.
38. Yamaguchi G, Takanashi M, Tanaka M, Fujita K, Ohira T, Kuroda M, et al. Isolation of miRNAs that target EGFR mRNA in human lung cancer. Biochem Biophys Res Commun 2012;420:411-6.
39. Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012;22:318-30.
40. Dube PE, Yan F, Punit S, Girish N, McElroy SJ, Washington MK, et al. Epidermal growth factor receptor inhibits colitis-associated cancer in mice. J Clin Invest 2012;122:2780-92.